论文部分内容阅读
Platelet hyper-aggregability triggered death and disability due to cardiovascular diseases is increasing worldwide and becoming a global concern. Therefore, it is necessary to synthesize newer drugs for the management of platelet aggregation. In this study, we investigated the antiplatelet aggregation activity of a novel series of ferrocenylimine compounds(3–10), N-(3-nitro-2-hydroxylbenzylidene)-3-ferrocenylimine(3), N-(3-bromo-2-hydroxylbenzylidene)-3-ferrocenylimine(4), N-(3-bromo-5-chlorosalicylidene)-3-ferrocenylimine(5), N-(ferrocenylformidene)-3-ferrocenylimine(6), N-(3-nitro-2-hydroxylbenzylidene)-4-ferrocenylimine(7), N-(3-bromo-2-hydroxylbenzylidene)-4-ferrocenylimine(8), N-(3-bromo-5-chlorosalicyl)-4-ferrocenylimine(9), N-(ferrocenylformidene)-4-ferrocenylimine(10) on thrombin-and ADP-induced platelet aggregation. The synthesized ferrocenylimine compounds(3–10) were found to exhibit higher antiplatelet aggregation activity than their precursors, which are 3-ferrocenylaniline(compound 1) and 4-ferrocenylaniline(compound 2). Among the derivatives, compounds 5, 6 and 10 possessed excellent platelet aggregation inhibition against the agonists.
Platelet hyper-aggregability triggered death and disability due to cardiovascular diseases is increasing worldwide and becoming a global concern. Thus, it is necessary to synthesize newer drugs for the management of platelet aggregation. In this study, we investigated the antiplatelet aggregation activity of a novel series of ferrocenylimine compounds (3-10) N- (3-bromo-2-hydroxybenzylidene) -3-ferrocenylimine 3-ferrocenylimine (5), N- (3-bromo-5- chlorosalicylidene) -3-ferrocenylimine 3-bromo-2-hydroxylbenzylidene-4-ferrocenylimine (8), N- (3-bromo-5- chlorosalicyl) -4-ferrocenylimine The synthesized ferrocenylimine compounds (3-10) were found to exhibit higher antiplatelet aggregation activity than their precursors, which are 3-ferrocenylani Among the compounds, compounds 5, 6 and 10 possessed excellent platelet aggregation inhibition against the agonists.